All articles by
GSK sues Pfizer for alleged RSV vaccine patent infringement
In the lawsuit filed in federal court in Delaware, GSK alleged that Pfizer used many of its vaccine ingredients, covered by GSK patents, without permission as well as the processes used to produce these components
Aravive’s batiraxcept fails to meet primary point in Phase 3 ovarian cancer study
The company will continue to assess the entire dataset of the late-stage study to determine the drug candidate’s further development steps
FACIT, T-CAIREM at the University of Toronto join forces to commercialise medical AI
The collaboration intends to leverage T-CAIREM’s translational research in AI and FACIT’s unique commercialisation-venture model to foster the growth of the next generation of biotechnology companies in Ontario
Grünenthal announces joint venture collaboration with Kyowa Kirin
Under the collaboration, all the products in the portfolio will continue to be marketed through affiliates in seven major European countries
Prometheus Laboratories and Fresenius Kabi partner on Anser testing
Anser TDM services, a range of homogenous mobility shift tests, are said to be useful for clinicians who treat immune-mediated conditions like inflammatory bowel disease and rheumatoid arthritis
Revolution Medicines agrees to buy US drugmaker EQRx
The transaction is intended to add more than $1bn in net cash to Revolution Medicines’ balance sheet and increase Revolution’s efforts to discover, develop and deliver RAS(ON) Inhibitor drugs
ProQR to divest sepofarsen and ultevursen ophthalmic assets to Théa
Under the terms of the agreement, ProQR will get an initial payment of €12.5m and will also be eligible for up to €135m in further development, regulatory, and commercial payments
Viatris, Kindeva roll out Breyna Inhalation Aerosol for asthma and COPD patients
Breyna is said to be the first generic version of AstraZeneca’s Symbicort with US Food and Drug Administration (FDA)-approved Abbreviated New Drug Application (ANDA)
Marinus’ Ztalmy gets EC approval for adjunctive treatment of epileptic seizures
The approval was backed by the results from the Phase 3 trial in which Ztalmy showed a median 30.7% reduction in 28-day major motor seizure frequency against a median 6.9% reduction in the placebo group
Biogen agrees to buy Reata Pharmaceuticals for $7.3bn
Reata is a global biopharmaceutical company dedicated to advancing novel therapeutics for individuals facing serious or life-threatening diseases and engaged in developing and bringing innovative treatments specifically designed for patients with limited or no approved therapeutic options available to them